A 48-year-old man with a history of recurrent biliary colic presents with jaundice, pale stools, and dark urine. Liver function tests show elevated conjugated bilirubin (4.2 mg/dL) and alkaline phosphatase (320 U/L). Ultrasound abdomen shows dilated intrahepatic and extrahepatic bile ducts with a 6 mm common bile duct, but no stone is visualized. What is the most appropriate next investigation to diagnose choledocholithiasis?

Explanation

## Investigation of Choice for Suspected Choledocholithiasis **Key Point:** MRCP (Magnetic Resonance Cholangiopancreatography) is the investigation of choice for diagnosing choledocholithiasis when ultrasound is inconclusive or negative despite clinical and biochemical evidence of biliary obstruction. ### Why MRCP is Optimal **Diagnostic Accuracy:** - **Sensitivity:** 90–95% for detecting CBD stones ≥5 mm. - **Specificity:** 98–99% for CBD stones. - **Non-invasive:** No risk of pancreatitis (unlike ERCP). - **High-resolution imaging:** Provides excellent visualization of the entire biliary tree, including intrahepatic ducts. **Mechanism:** - MRCP uses T2-weighted MRI sequences to image fluid (bile) within the biliary system. - Stones appear as filling defects within the CBD. - Bile duct dilatation and level of obstruction are clearly delineated. ### Clinical Scenario Analysis In this patient: - **Clinical signs:** Jaundice, pale stools, dark urine → biliary obstruction. - **Biochemistry:** Elevated conjugated bilirubin and alkaline phosphatase → cholestasis. - **Ultrasound findings:** Dilated ducts (intrahepatic and extrahepatic) but **no stone visualized** → ultrasound has 60–70% sensitivity for CBD stones; negative ultrasound does not exclude choledocholithiasis. - **Indication for MRCP:** To definitively diagnose or exclude CBD stone before deciding on ERCP. **High-Yield:** MRCP is indicated when: - Ultrasound is negative or inconclusive but clinical/biochemical suspicion is high. - Need to confirm CBD stone before therapeutic ERCP. - Assess for microlithiasis or sludge in the CBD. - Evaluate for other causes of obstruction (stricture, malignancy). ### Comparison with Other Investigations | Investigation | Role | Sensitivity for CBD Stone | Specificity | When to Use | |---|---|---|---|---| | **Ultrasound** | First-line | 60–70% | 95% | Initial screening; limited by operator dependence | | **MRCP** | Gold standard (non-invasive) | 90–95% | 98–99% | Confirm CBD stone; plan ERCP | | **ERCP** | Therapeutic + diagnostic | 95–98% | 99% | When stone confirmed and removal planned | | **CT (multidetector)** | Detects stones ≥4 mm | 85–90% | 95% | Useful but inferior to MRCP for CBD stones | | **EUS** | High sensitivity for small stones | 95–98% | 98% | Operator-dependent; not first-line | **Clinical Pearl:** MRCP is the **bridge investigation** between inconclusive ultrasound and therapeutic ERCP. It confirms the diagnosis without the risk of post-ERCP pancreatitis and allows selective use of ERCP only when a stone is confirmed. ### Mnemonic: **MRCP Advantages** - **M**agnetic (non-invasive, no contrast needed) - **R**eliable (90–95% sensitivity) - **C**lear (excellent anatomic detail) - **P**erfect (98–99% specificity)